Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies

NCT04283006 is registered in ClinicalTrials.gov with He Huang as lead sponsor.

NCT NCT04283006
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04283006 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study of CD20/CD22 Targeted CAR T-cell Therapy for Relapsed or Refractory Lymphoid Malignancies
Lead sponsor
He Huang
Phase
Phase 1
Overall status
Recruiting
Start date
May 23, 2018
Completion date
May 23, 2028
Enrollment
100 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

lymphoid hematological malignancies, relapsed and refractory